Lipocine receives CRL

The Food and Drug Administration issued a Complete Response Letter to Lipocine Inc. (Nasdaq: LPCN) for LPCN 1021. Shares of the specially pharmaceutical plummeted $3.17 to close at $3.10.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.